
|Articles|June 15, 2003
Bausch & Lomb to delay regulatory filing
Rochester, NY-Bausch & Lomb will delay the regulatory filing for the intravitreal fluocinolone acetonide implant (Retisert), a treatment for diabetic macular edema (DME), for up to 3 years while the FDA reviews 12-month safety data of additional eyes treated with implants.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Redefining glaucoma care: Where innovation meets clinical insight
3
Beyond the surface: Tackling complex dry eye cases
4
Seborrheic dermatitis linked to multiple epithelial barrier diseases
5



















































.png)


